Elevation of the glycoxidation product Nε-(carboxymethyl) lysine in patients presenting with acute myocardial infarction

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 4, 2009, Pages 446-451

  Kralev, Stefan ^a,b   Zimmerer, Elke ^a   Brueckmann, Martina ^a   Lang, Siegfried ^a   Kälsch, Thorsten ^a   Rippert, Anja ^a   Lin, Jihong ^a   Borggrefe, Martin ^a   Hammes, Hans Peter ^a   Süselbeck, Tim ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Advanced glycation end products; Endothelial dysfunction; Myocardial infarction; N (carboxymethyl)lysine

Indexed keywords

LYSINE; N EPSILON (CARBOXYMETHYL)LYSINE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; AMINO ACID BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GLYCATION; GLYCOSIDATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ST SEGMENT ELEVATION;

ACUTE DISEASE; AGED; FEMALE; GLYCOSIDES; HUMANS; LYSINE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIDATION-REDUCTION;

EID: 63849199788     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.100     Document Type: Article

References (48)

1. USA National Vital Statistics Report. 2004;53(5).
2. Lupi HE, Chuquiure VE, Gaspar HJ, Ferez Santander SM. From the single vulnerable plaque, to the multiple complex coronary plaques. From their basis, to the modern therapeutic approach. A clinical reality in the spectrum of the acute coronary syndromes. Arch Cardiol Mex 2006;76:239-40.
3. Theroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, et al. Prognostic significance of blood markers of inflammation in patients with STsegment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 2005;26:1964-70.
4. Lieuw-a-Fa ML, Schalkwijk CG, Engelse M, van Hinsbergh VW. Interaction of Nepsilon(carboxymethyl) lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. Thromb Haemost 2006;95:320-8.
5. Fu S, Fu MX, Baynes JW, Thorpe SR, Dean RT. Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins. Biochem J 1998;330:233-9.
6. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271:9982-6.
7. Hammes HP, Brownlee M, Lin J, Schleicher E, Bretzel RG. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl)lysine independently of glycohaemoglobin concentrations. Diabetologia 1999;42:603-7.
8. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004;110:588-636.
9. Hammes HP, Alt A, Niwa T, Clausen JT, Bretzel RG, Brownlee M, et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999;42:728-36.
10. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, et al. N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996;35:8075-83.
11. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995;34:10872-8.
12. Eble AS, Thorpe SR, Baynes JW. Nonenzymatic glycosylation and glucose-dependent cross-linking of proteins. J Biol Chem 1983;258:9406-12.
13. Peppa M, Uribarri J, Vlassara H. Advanced glycoxidation: a new risk factor for cardiovascular disease? Cardiovasc Toxicol 2002;2:275-87.
14. Peppa M, Uribarri J, Vlassara H. The role of advanced glycation end products in the development of atherosclerosis. Curr Diab Rep 2004;4:31-6.
15. Nerlich AG, Schleicher ED. N(epsilon)-(carboxymethyl) lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Atherosclerosis 1999;144:41-7.
16. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxy- methyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997;99:457-68.
17. Haslbeck KM, Schleicher ED, Friess U, Kirchner A, Neundorfer B, Heuss D. N(epsilon)-(carboxymethyl)lysine in diabetic and non-diabetic polyneuropathies. Acta Neuropathol (Berl) 2002;104:45-52.
18. Czaja MJ. Induction and regulation of hepatocyte apoptosis by oxidative stress. Antioxid Redox Signal 2002; 4:759-67.
19. Dunn JA, Patrick JS, Thorpe SR, Baynes JW. Oxidation of glycated proteins: age-dependent accumulation of N epsilon-(carboxymethyl)lysine in lens proteins. Biochemistry 1989;28:9464-8.
20. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995; 270:10017-26.
21. Dunn JA, Ahmed MU, Murtiashaw MH, Richardson JM, Walla MD, Thorpe SR, et al. Reaction of ascorbate with lysine and protein under autoxidizing conditions: formation of N epsilon-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 1990;29:10964-70.
22. Wells-Knecht KJ, Zyzak DV, Lichtfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995;21:3702-9.
23. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of "autoxidative glycosylation" in diabetes. Biochem J 1987;245:243-50.
24. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103-13.
25. Palinski W, Koschinsky T, Butler SW, Miller E, Vlassara H, Cerami A, et al. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 1995;15:571-82.
26. Stitt AW, He C, Friedman S, Scher L, Rossi P, Ong L, et al. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med 1997;3:617-27.
27. Ballinger ML, Thomas MC, Nigro J. Glycated and carboxy-methylated proteins do not directly activate human vascular smooth muscle cells. Kidney Int 2005;68: 2756-65.
28. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Y-S, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signalling pathways and modulate gene expression. J Biol Chem 1999;274:31740-9.
29. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LT, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001;21:905-10.
30. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17810-4.
31. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001;50:1495-1504.
32. Schalkwijk CG, Baidoshvili A, Stehouwer CD, van Hinsbergh VW, Niessen HW. Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl) lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim Biophys Acta 2004;1636:82-9.
33. Schmidt AM, Yan SD, Stern DM. The dark side of glucose. Nat Med 1995;1:1002-4.
34. Camejo G. The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: its possible role in atherogenesis. Adv Lipid Res 1982;19:1-53.
35. Little PJ, Tannock L, Olin KL, Chait A, Wight TN. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta 1 exhibit increased binding to LDLs. Arterioscler Thromb Vasc Biol 2002;22:55-60.
36. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002;417:750-4.
37. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001;88: 10K-5K.
38. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
39. Falk E, Fernandez-Ortiz A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol 1995; 23:3B-11B.
40. Brueckmann M, Bertsch T, Lang S, Sueselbeck T, Wolpert C, Kaden JJ, et al. Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes. Clin Chem Lab Med 2004;42:1132-9.
41. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6.
42. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid, a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
43. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.
44. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5-12.
45. Garcia-Moll X, Coccolo F, Cole D, Kaski JC. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol 2000;35:956-62.
46. Spagnoli LG, Bonanno E, Mauriello A, Palmieri G, Partenzi A, Sangiorgi G, et al. Multicentric inflammation in epicardial coronary arteries of patients dying of acute myocardial infarction. J Am Coll Cardiol 2002;40:1579-88.
47. Zairis MN, Papadaki OA, Manousakis SJ, Thoma MA, Beldekos DJ, Olympios CD, et al. C-reactive protein and multiple complex coronary artery plaques in patients with primary unstable angina. Atherosclerosis 2002;164:355-9.
48. Baidoshvili A, Krijnen PA, Kupreishvili K, Ciurana C, Bleeker W, Nijmeijer R, et al. N(epsilon)-(carboxymethyl) lysine depositions in intramyocardial blood vessels in human and rat acute myocardial infarction: a predictor or reflection of infarction? Arterioscler Thromb Vasc Biol 2006;26:2497-503.